300+ investors in your industry, stage, and region Get
Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Financial Services
Construction
Mobile
Photography
Cryptocurrency
Digital Media
Big Data
Artificial Intelligence
Clean Energy
Non Profit
Social Impact
Energy
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Local
Travel
Platforms
InsurTech
Email
Oil and Gas
Film
Retail
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Medical Device
Wellness
Education
Sports
Legal
Automotive
eSports
Biotechnology
Renewable Energy
Facebook
Software
Blockchain
Theatre
Medical
Web3
Beauty
Recruiting
Celebrity
Cannabis
LGBT
Climate
Food and Beverage
Life Science
Publishing
Wine and Spirits
Fashion
Mobile Apps
Real Estate
Sporting Goods
Music
Art
Finance
Manufacturing
FinTech
Social Media
Franchise
Internet
Mobile Advertising
Android
Impact
Proptech
Hardware
Transportation
Biotech
Sustainability
Enterprise
Community
Media (Entertainment)
Infrastructure
Social
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Singapore
Burkina Faso
Africa
LATAM
Egypt
United Kingdom
Faroe Islands
South Korea
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Haiti
Sudan
Malawi
Isle of Man
Iran
Madagascar
Lesotho
Russian Federation
Turkey
Liberia
Nepal
Pakistan
Mexico
Tajikistan
Sweden
Zambia
Romania
Oceania
Argentina
Tunisia
Taiwan
Zimbabwe
Oman
Poland
Puerto Rico
Guernsey
Cameroon
Colombia
China
Armenia
Costa Rica
Côte d'Ivoire
Czech Republic
Kuwait
Marshall Islands
Malta
Luxembourg
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
Morocco
New Zealand
Jamaica
Sri Lanka
Kazakhstan
Guatemala
Switzerland
Venezuela
Cayman Islands
Myanmar
Uganda
Uruguay
Moldova
Botswana
Seychelles
Paraguay
South Africa
France
Denmark
Ghana
Georgia
Iraq
Philippines
Portugal
Sierra Leone
El Salvador
India
Senegal
Germany
Ireland
Canada
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Dominican Republic
Asia
Bermuda
Albania
Spain
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Angola
Azerbaijan
Europe
Ecuador
Bulgaria
Bahamas
Bahrain
Cyprus
Jersey
Estonia
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Qatar
Grenada
Israel
Honduras
Lithuania
Cambodia
Iceland
Lebanon
Liechtenstein
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Aberdeen Investments, VC Fund

Aberdeen Investments

VC Fund

Scotland, United States

Aberdeen Investments is a VC fund in Scotland focused on Medical and Health Care. Aberdeen Investments is focused on expanding our direct and advised wealth platforms, as well as repositioning our professional asset management business to suit client demand.

Total investments:
7
Last investment:
Lead investor:
43%

Last updated:

Industries Aberdeen Investments invests in

MedicalHealth CareBiotechnologyLife ScienceTherapeutics

Stages Aberdeen Investments invests in

Post-IPO EquitySeries APost-IPO DebtCorporate Round

Countries Aberdeen Investments invests in

United StatesSpain

Investment Focus

Industry

  • Medical 3 (43%)
  • Health Care 3 (43%)
  • Biotechnology 3 (43%)
  • Life Science 2 (29%)
  • Therapeutics 2 (29%)
See all 14 industries →

Stage

  • Post-IPO Equity 3 (43%)
  • Series A 1 (14%)
  • Post-IPO Debt 1 (14%)
  • Corporate Round 1 (14%)

Country

  • United States 4 (57%)
  • Spain 1 (14%)

Investments

CompanyDescriptionRoundLinks
ACCIONA ACCIONA
ACCIONA is one of the foremost Spanish business corporations, leader in the development and management of infrastructure, renewable energy, water and services. Listed on the selective Ibex-35 stock exchange index, it is a benchmark for the market. The Company was set up over a century ago and is made up of more than 30,000 employees and has apresence in more than 30 countries on five continents. See more at: http://www.acciona.com Post-IPO Debt / Jul 31, 2026
Velian
Velian is a European e-mobility infrastructure provider that designs, builds, and operates EV charging networks for public, logistics, and real estate clients. It designs, finances, builds, and operates EV charging infrastructure. Corporate Round / May 18, 2026
Immunic Therapeutics Immunic Therapeutics
Immunic, Inc. is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolismof activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. $400M / Post-IPO Equity / Feb 13, 2026
Third Arc Bio Third Arc Bio
Third Arc Bio is a biotech company developing multifunctional antibodies for inflammatory and immunology diseases. Its drug development engine delivers superior biologics optimized to create T-cell engagement by leveraging two technologies that power a pipeline of high-value therapeutics – a solid tumor synergy platform and an I&I platformthat offers a novel approach to precision immune regulation at a tissue-specific level to achieve superior efficacy and safety. $52M / Series A / Feb 04, 2026
Precision BioSciences Precision BioSciences
Precision BioSciences is a biotechnology company dedicated to improving lives through its next-generation gene editing technology, ARCUS.Precision BioSciences’ mission is to translate the world’s most powerful genome editing technology into greatly needed products throughout the life sciences. Precision’s proprietary ARCUS genome editingtechnology enables the production of highly specific nucleases that can insert, remove, and modify DNA at essentially any location in a complex genome. $75M / Post-IPO Equity / Nov 10, 2025
Jade Biosciences Jade Biosciences
Jade Biosciences is developing transformative therapies to redefine the standard of care for inflammation and immunology indications. $135M / Post-IPO Equity / Oct 07, 2025
Immunic Therapeutics Immunic Therapeutics
Immunic, Inc. is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolismof activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. $5.1M / Post-IPO Equity / Apr 09, 2025

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Financial Services
Construction
Mobile
Photography
Cryptocurrency
Digital Media
Big Data
Artificial Intelligence
Clean Energy
Non Profit
Social Impact
Energy
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Local
Travel
Platforms
InsurTech
Email
Oil and Gas
Film
Retail
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Medical Device
Wellness
Education
Sports
Legal
Automotive
eSports
Biotechnology
Renewable Energy
Facebook
Software
Blockchain
Theatre
Medical
Web3
Beauty
Recruiting
Celebrity
Cannabis
LGBT
Climate
Food and Beverage
Life Science
Publishing
Wine and Spirits
Fashion
Mobile Apps
Real Estate
Sporting Goods
Music
Art
Finance
Manufacturing
FinTech
Social Media
Franchise
Internet
Mobile Advertising
Android
Impact
Proptech
Hardware
Transportation
Biotech
Sustainability
Enterprise
Community
Media (Entertainment)
Infrastructure
Social
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Singapore
Burkina Faso
Africa
LATAM
Egypt
United Kingdom
Faroe Islands
South Korea
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Haiti
Sudan
Malawi
Isle of Man
Iran
Madagascar
Lesotho
Russian Federation
Turkey
Liberia
Nepal
Pakistan
Mexico
Tajikistan
Sweden
Zambia
Romania
Oceania
Argentina
Tunisia
Taiwan
Zimbabwe
Oman
Poland
Puerto Rico
Guernsey
Cameroon
Colombia
China
Armenia
Costa Rica
Côte d'Ivoire
Czech Republic
Kuwait
Marshall Islands
Malta
Luxembourg
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
Morocco
New Zealand
Jamaica
Sri Lanka
Kazakhstan
Guatemala
Switzerland
Venezuela
Cayman Islands
Myanmar
Uganda
Uruguay
Moldova
Botswana
Seychelles
Paraguay
South Africa
France
Denmark
Ghana
Georgia
Iraq
Philippines
Portugal
Sierra Leone
El Salvador
India
Senegal
Germany
Ireland
Canada
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Dominican Republic
Asia
Bermuda
Albania
Spain
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Angola
Azerbaijan
Europe
Ecuador
Bulgaria
Bahamas
Bahrain
Cyprus
Jersey
Estonia
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Qatar
Grenada
Israel
Honduras
Lithuania
Cambodia
Iceland
Lebanon
Liechtenstein
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Aberdeen Investments invest in?

Aberdeen Investments invests primarily in Medical, Health Care and Biotechnology startups, most often at Post-IPO Equity and Series A stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

When did Aberdeen Investments last invest?

The most recent investment recorded for Aberdeen Investments closed in Jul 2026. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Aberdeen Investments Aberdeen Investments Find emails